Julián Andrés Murillo Palacios

Internista y hematólogo. Progresista y respetuoso de las libertades.

[Benlazar S M A @smbenlazar]

Glofitamab crosses the blood-brain barrier and exhibits activity against primary and secondary CNS lymphoma https://t.co/94OgAHK1fY #lymsm

[Laura Korin @laura_korin]

The future is exciting for 1L DLBCL! @AndyD1036 shares his perspective on how we will choose the optimal option for our patients if various phase 3 trials turn positive: effect size, toxicity profile, ease of delivery and economic aspects

[Vincent Rajkumar @VincentRK]

Just out! All you need to know about Smoldering Mulitple Myeloma. Our comprehensive Review in @NatRevClinOncol
Bookmark!

@ZanwarSaurabh @myelomaMD @MayoCancerCare @SpringerNature

For limited time free access: https://t.co/UGbI3m6Mls

[Abdul Muqtadir Abbasi @AbbasiMuqtadir]

Multiple Myeloma one page says it all. According to IMWG criteria.

Save, learn and share.

#MedTwitter

[Benlazar S M A @smbenlazar]

Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial https://t.co/tZt5j4mmQz #leusm

[Benlazar S M A @smbenlazar]

Updates in low/intermediate-risk MDS https://t.co/71y4fRYXFj #mds

[Benlazar S M A @smbenlazar]

Choosing the optimal maintenance strategy in multiple myeloma https://t.co/1ELx4U9Qim #ASH25 #mmsm

[Mehmet S. UYANIK @UyanikMehmetS]

A very important table for hematologist from the article:
https://t.co/qOFXTp9pFp

[Vincent Rajkumar @VincentRK]

Updated mSMART guidelines on treatment of newly diagnosed myeloma.

Major change: For standard risk myeloma, doublet maintenance (lenalidomide plus anti CD38) recommended if MRD+ post transplant.

https://t.co/R4hz7ulYPb

[Dr. Chokri Ben Lamine @abouabdrahman0]

🔥 Point Mutations in Hematology – 50 High-Yield Examples (Silent 🟡 / Missense 🟠 / Nonsense 🔴)

✅ | Boards ✅ | Benign + Malignant ✅)

🧬 Missense Mutations (Amino acid change) 🟠
1.JAK2 V617F → PV/ET/MF
2.CALR L367fs*46 (frameshift but behaves like missense-like effect) → ET/MF
3.MPL W515L/K → ET/MF
4.KIT D816V → Systemic Mastocytosis
5.FLT3 D835Y → AML
6.IDH1 R132H → AML
7.IDH2 R140Q/R172K → AML
8.NRAS G12D → AML/MDS
9.KRAS G13D → AML
10.TP53 R175H → High-risk MDS/AML, Li-Fraumeni
11.CEBPA N321D → AML
12.SF3B1 K700E → MDS-RS
13.NOTCH1 P2514fs → T-ALL
14.BRAF V600E → Hairy Cell Leukemia
15.MYD88 L265P → Waldenström macroglobulinemia
16.EZH2 Y646N → FL/DLBCL
17.GATA2 T354M → MonoMAC immunodeficiency → MDS
18.PIGA mutations → PNH
19.HBB E6V → Sickle Cell Disease
20.HFE C282Y → Hereditary Hemochromatosis

⸻

🧬 Nonsense Mutations (Premature STOP codon) 🔴
21. RUNX1 R139X → Familial Platelet Disorder → AML
22. ETV6 Q347X → Familial ALL
23. DNMT3A R882X → AML
24. CSF3R Q741X → SCN → AML transformation
25. HBB Q39X → β-Thalassemia major
26. HBA1 W15X → α-Thalassemia
27. FANCA W349X → Fanconi anemia
28. TP53 R213X → MDS/AML
29. SBDS R126X → Shwachman-Diamond → AML risk
30. BRCA2 K3326X → DNA repair (t-AML risk)

⸻

🧬 Silent Mutations (No amino acid change but pathogenic!) 🟡
31. GATA1 silent exon mutation → Diamond-Blackfan anemia
32. BCL2 silent regulatory mutation → FL expression dysregulation
33. HBB c.315+16G>C → splicing β-thalassemia
34. CFTR silent carriers increase leukemia risk with chemo exposure
35. ATM silent regulatory mutation → t-MDS risk
36. HBA2 silent duplication → α-Thal trait
37. TPMT silent SNPs → thiopurine metabolism in ALL treatment
38. NQO1 C609T silent → pediatric AML risk
39. HFE H63D silent effect → iron overload modifier
40. VKORC1 silent SNP → affects warfarin dosing in hematology patients

⸻

🧬 Bonus High-Yield Mutations (Hematology Boards) 🎯
41. JAK2 exon 12 → JAK2 V617F negative PV
42. NPM1 exon 12 4bp insertion → AML with good chemo sensitivity
43. FLT3 ITD → AML adverse risk
44. TET2 frameshift → CHIP/MDS
45. ASXL1 G646WfsX → MDS/CMML poor risk
46. CBL missense → JMML
47. U2AF1 S34F → MDS
48. PHF6 nonsense → T-ALL
49. LSD1 K661A → Epigenetic AML mutation
50. SRP72 mutation → familial aplastic anemia → MDS

Credits for sharing for Dr Osman Ahmad

#hemaboard

[ILLIASUL IBAD @IlliasulK]

Every time I heard Erdheim–Chester or Rosai–Dorfman I was 🤯 confused.
“What is this? Definitely not my cup of tea!”

But once you know the key difference 👇

•Erdheim–Chester → CD68+, CD1a–, Touton giant cells

•Langerhans → CD68+, CD1a+, S100+

•Rosai–Dorfman → CD68+, CD1a–, S100+, emperipolesis

Trust me—suddenly it all makes sense. 🧩

#Rheumatology #Immunology
#Sullysrounds #MedX #Medtwitter #Mnemonics #Medicine #History
@DrAkhilX @IhabFathiSulima @Janetbirdope @Lupusreference @RheumNow #MedTwitter #RheumTwitter
@drkeithsiau

[Benlazar S M A @smbenlazar]

Acute lymphocytic leukaemia - The Lancet https://t.co/BHu2vuPOnv #leusm

[Benlazar S M A @smbenlazar]

Monoclonal Gammopathy of Undetermined Significance | New England Journal of Medicine https://t.co/8j5sVueAW3 #MMSM #MGUS

[Côme Bommier @ComeBommier]

The 2025 LBCL Guidelines are out !

Fantastic work made by the @EHA_Hematology

Cc @c_thieblemont

https://t.co/OR8RZ95Wt3

[Ahmed Kotb @AhmedKo45911157]

🩸Managing Platelet Refractoriness
🔍Suboptimal post-transfusion increment?
➡️Rule out non-immune causes (🦠infection,💊meds)
🧬Check for immune causes (HLA, HPA, ABO Abs)
🧪Use ELISA, Luminex, or flow cytometry
🎯HLA-selected platelets for true immune cases
📚 Nahirniak.Blood.23

[Uriel Suárez @UsuarezMD]

R-mini-CHOP. 2011.

https://t.co/Fr9VgpivTk

[Jasmine Sethi @JasmineNephro]

✅Revised criteria for diagnosis of Antiphospholipid syndrome APS

@KIReports

https://t.co/scHLgp7sGW

[Haematologica @Haematologica]

Review article: a new comprehensive analysis of the molecular mechanisms driving chronic myelomonocytic leukemia and its clinical manifestations within the ever-evolving landscape of precision medicine.
https://t.co/3Yk31WGjPD

[Benlazar S M A @smbenlazar]

Peripheral T-cell lymphomas https://t.co/gjOiWxvssu #lymsm